Supplementary material Supplementary Table 1. Recoveries in liver Supplementary 2. Matrix effects liver Supplementary Table 3. Matrix effects plasma Supplementary 4. Sample stabilities Supplementary Table 5. Phenotypic characteristics of STZ-treated and healthy control mice Supplementary 6. Acylcarnitine concentrations in plasma and liver tissue from STZ-treated mice and healthy controls Supplementary Table 1. Recoveries in liver Liver spiked Recovery (nmol/mg) (%) 0.4 87.3 1 77.3 C0 2 68.5 0.4 86.7 1 71.5 C2 2 59.5 0.4 81.5 1 75.0 C3 2 59.5 0.4 86.4 1 81.8 2-M-C3 2 71.2 0.4 86.4 1 74.3 C4 2 59.4 0.4 95.3 1 86.3 3-M-C4 2 89.4 0.4 86.3 1 77.7 C5 2 69.8 0.4 89.0 1 80.0 C6 2 72.4 0.4 92.6 1 84.9 C8 2 86.3 0.4 98.4 1 88.7 C10 2 90.8 0.4 97.0 C12 1 86.2
Supplementary material Supplementary Table 1. Recoveries in liver Supplementary 2. Matrix effects liver Supplementary Table 3. Matrix effects plasma Supplementary 4. Sample stabilities Supplementary Table 5. Phenotypic characteristics of STZ-treated and healthy control mice Supplementary 6. Acylcarnitine concentrations in plasma and liver tissue from STZ-treated mice and healthy controls Supplementary Table 1. Recoveries in liver Liver spiked (nmol/mg) Recovery (%) C0 0.4 87.3 1 77.3 2 68.5 C2 0.4 86.7 1 71.5 2 59.5 C3 0.4 81.5 1 75.0 2 59.5 2-M-C3 0.4 86.4 1 81.8 2 71.2 C4 0.4 86.4 1 74.3 2 59.4 3-M-C4 0.4 95.3 1 86.3 2 89.4 C5 0.4 86.3 1 77.7 2 69.8 C6 0.4 89.0 1 80.0 2 72.4 C8 0.4 92.6 1 84.9 2 86.3 C10 0.4 98.4 1 88.7 2 90.8 C12 0.4 97.0 1 86.2
jlr.D061721-1.docx